Article
Oncology
Er Yue, Guangchao Yang, Yuanfei Yao, Guangyu Wang, Atish Mohanty, Fang Fan, Ling Zhao, Yanqiao Zhang, Tamara Mirzapoiazova, Tonya C. Walser, Lorna Rodriguez-Rodriguez, Yuman Fong, Ravi Salgia, Edward Wenge Wang
Summary: Ovarian cancer is a deadly disease with urgent need for new treatments. The development of a conditionally replicative oncolytic adenovirus (CRAd) that targets MUC16/CA-125 in cancer cells shows promising anti-cancer effects. This approach represents a unique and practical direction for further investigation in ovarian cancer treatment.
Article
Chemistry, Multidisciplinary
Julian Matthias Metzler, Daniel Fink, Patrick Imesch
Summary: Ibrutinib, a small-molecule inhibitor of Bruton's tyrosine kinase, is used to treat hematological diseases like chronic lymphocytic leukemia. The hypothesis that it may suppress the tumor marker CA-125 in ovarian cancer is based on an observation in a patient with low-grade serous ovarian cancer who received ibrutinib for CLL. A mechanistic model explaining this potential drug effect is proposed for further research.
APPLIED SCIENCES-BASEL
(2021)
Article
Biochemistry & Molecular Biology
Lars Schroeder, Christian M. Domroese, Alexander B. A. Rupp, Kathrin M. E. Gihr, Christoph Niederau, Michael R. Mallmann, Stefan Holdenrieder
Summary: This study found that CA-125 and TPA showed promising results as screening tools for ovarian or uterine cancer. Both biomarkers were able to discriminate between malignant and non-malignant cases in the overall sample. However, TPA was the best diagnostic marker for uterine cancer, while CA-125 was the best for ovarian cancer.
Article
Oncology
Roli Purwar, Kishan Soni, Ragini Tilak, Ashish Verma, Manoj Pandey
Summary: Peritonitis associated with Curvularia lunata is rare, with only five cases reported in the literature, all in middle-aged patients with comorbidities undergoing dialysis. This case report presents a 21-year-old female patient who was diagnosed with ovarian malignancy based on raised CA 125 and suspected tubo-ovarian mass on MRI, but was later found to have a pelvic collection with Curvularia lunata infection.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2022)
Article
Medicine, General & Internal
Phichayut Phinyo, Jayanton Patumanond, Panprapha Saenrungmuaeng, Watcharin Chirdchim, Tanyong Pipanmekaporn, Apichat Tantraworasin, Theera Tongsong, Charuwan Tantipalakorn
Summary: The study demonstrated that the model combining IOTA Simple Rules and serum CA-125 information was significantly superior in predicting the malignant potential of ovarian tumors compared to using only IOTA Simple Rules. This model, known as the IOTA SR X CA-125 model, showed high discriminative ability and could potentially aid in guiding patient referrals to oncologic specialists.
Article
Biochemical Research Methods
Jin Song, Lori J. J. Sokoll, Zhen Zhang, Daniel W. W. Chan
Summary: Close to 75% of ovarian cancer cases are diagnosed at an advanced stage, with a high rate of relapse after primary therapy. Therefore, it is crucial to identify strategies for early detection of ovarian cancer recurrence to improve outcomes.
CLINICAL PROTEOMICS
(2023)
Article
Immunology
Lingeng Lu, Wenxue Ma, Caroline H. Johnson, Sajid A. Khan, Melinda L. Irwin, Lajos Pusztai
Summary: Somatic mutation-derived neoantigens are used to develop an mRNA vaccine targeting CA-125 neoantigen for breast and ovarian cancer. Immuno-bioinformatics tools were used to predict CD8' T cell epitopes and a self-adjuvant mRNA vaccine was constructed to enhance cross-presentation by dendritic cells. Immune responses post-immunization were estimated using an in silico algorithm, showing IFN-c and CD8' T cell response. The strategy described in this study can be used to design precision multi-epitope mRNA vaccines targeting multiple neoantigens.
Article
Oncology
Christoph Wohlmuth, Vladimir Djedovic, Susanne K. Kjaer, Allan Jensen, Rosalind Glasspool, Patricia Roxburgh, Anna DeFazio, Sharon E. Johnatty, Penelope M. Webb, Francesmary Modugno, Diether Lambrechts, Joellen M. Schildkraut, Andrew Berchuck, Liv Cecilie Vestrheim Thomsen, Line Bjorge, Estrid Hogdall, Claus K. Hogdall, Ellen L. Goode, Stacey J. Winham, Keitaro Matsuo, Beth Y. Karlan, Jenny Lester, Marc T. Goodman, Pamela J. Thompson, Tanja Pejovic, Marjorie J. Riggan, Katherine Lajkosz, Alicia Tone, Taymaa May
Summary: This study analyzed data from 176 women with low-grade serous ovarian cancer through a multi-center collaborative effort, revealing that elevated post-treatment CA-125 levels are significantly associated with poor survival, while FIGO staging and residual disease also impact patient outcomes.
Review
Oncology
Qingyi Wang, Xiaoling Feng, Xiaofang Liu, Siyu Zhu
Summary: According to the meta-analysis, higher pretreatment serum CA-125 levels are associated with poor prognosis in epithelial ovarian cancer (EOC) patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Chemistry, Analytical
Omer Faruk Er, Hilal Kivrak, Omruye Ozok, Sebahattin Celik, Arif Kivrak
Summary: The COVID-19 crisis has a serious impact on ovarian cancer patients, highlighting the importance of early detection. In this study, a PTTC-based sensor was designed to detect CA-125, a common marker for ovarian cancer, with higher precision and speed using electrochemical methods. The PTTC-based GCE electrode showed promising sensitivity and reliability for CA-125 detection, with optimum conditions determined as 3 μL PTTC loading, 5000 ng/mL CA125 antigen concentration, and 30 min incubation time. The linear range of this electrode was found to be 1-100 ng/mL, with a limit of detection of 0.0096 ng/mL and a limit of quantification of 0.0288 ng/mL. These findings suggest that PTTC is a novel and promising material for the detection of ovarian cancer antigen CA-125.
JOURNAL OF ELECTROANALYTICAL CHEMISTRY
(2022)
Article
Biotechnology & Applied Microbiology
Jessica de Souza Magalhaes, Millena Prata Jammal, Paula Carolina Arvelos Crispim, Eddie Fernando Candido Murta, Rosekeila Simoes Nomelini
Summary: The study found that CA-19.9 is useful in distinguishing between endometriomas and ovarian cancers, with a higher diagnostic value in endometriomas. Furthermore, the combination analysis of CA-125 and CA-19.9 can aid in differentiating endometriomas from other ovarian lesions.
Article
Multidisciplinary Sciences
Szymon Piatek, Grzegorz Panek, Zbigniew Lewandowski, Dominika Piatek, Przemyslaw Kosinski, Mariusz Bidzinski
Summary: The nadir CA-125 level in patients with epithelial ovarian cancer is associated with progression-free survival but not overall survival. Patients with nadir CA-125 levels between 11-35 U/ml after first-line treatment have a higher risk of recurrence compared to patients with levels <= 10 U/ml.
SCIENTIFIC REPORTS
(2021)
Article
Medicine, General & Internal
Seval Ay, Deniz Tataroglu Ozyukseler, Ozgecan Dulgar, Mustafa Basak, Mahmut Emre Yildirim, Mahmut Gumus
Summary: An observational study was conducted to investigate the relationship between the cut-off level of cancer antigen 125 (CA 125) and long-term prognosis in high-grade serous ovarian cancer (HGSCs). The results showed that initial CA 125 levels could predict disease-free and overall survival rates, with significant differences observed especially in stage III disease. This suggests that CA 125 level may have beneficial clinical predictive value for HGSC.
JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN
(2021)
Article
Biochemistry & Molecular Biology
Nattinee Krathumkhet, Toyoko Imae, Fu-ming Wang, Chiou-Chung Yuan, Jusni Manidae Lumban Gaol, Nophawan Paradee
Summary: In this study, a novel cancer antigen 125 (CA125) biomarker detection method based on electro-chemical immunosensor was demonstrated. The biomarker on conductive composite materials of carbon ink/carbon dot/zinc oxide (C-ink/CD/ZnO) was used as an electrode platform, enhancing the interaction of antibodies (Ab) with the catalytic performance of ZnO. The created immunosensor showed a wide linear range and low detection limit, making it an accurate and efficient diagnostic tool for CA125 and other biomarkers in clinical sample analysis.
BIOELECTROCHEMISTRY
(2023)
Review
Chemistry, Analytical
Mehrab Pourmadadi, Ali Moammeri, Amin Shamsabadipour, Yasamin Farahanian Moghaddam, Abbas Rahdar, Sadanand Pandey
Summary: Diagnosing early-stage cancers is crucial for saving lives and reducing mortality rates. Detection of the cancer antigen CA-125 is a key step in the treatment of certain cancers, such as ovarian cancer. This review discusses various optical and electrochemical methods for detecting CA-125, compares their performance and sensitivity, investigates commercial detection kits, and evaluates their applicability and accuracy.
